THE PLAZA AT LA JOLLA VILLAGE SMITH BARNEY TOWER SAN DIEGO, CALIFORNIA OFFICE LEASE AGREEMENT BETWEEN CA-LA JOLLA II LIMITED PARTNERSHIP, a Delaware limited partnership (“LANDLORD”) AND MEDICINOVA, INC., a Delaware corporation (“TENANT”)Office Lease Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • California
THIS OFFICE LEASE AGREEMENT (the “Lease”) is made and entered into as of the 28th day of January 2004, by and between CA-LA JOLLA II LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”) and MEDICINOVA, INC., a Delaware corporation (“Tenant”). The following exhibits and attachments are incorporated into and made a part of the Lease: Exhibit A (Outline and Location of Premises), Exhibit B (Expenses and Taxes), Exhibit C (Work Letter), Exhibit D (Commencement Letter), Exhibit E (Building Rules and Regulations). Exhibit F (Additional Provisions) and Exhibit G (Parking Agreement).
LICENSE AGREEMENTLicense Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) dated as of April 27, 2004 (“Effective Date”), is entered into between MediciNova, Inc., a Delaware corporation (“MN”) having a place of business located at 4350 La Jolla Village Drive, Ste 950, San Diego, California 92122, U.S.A., and Mitsubishi Pharma Corporation, a Japanese corporation (“MPC”), having a place of business located at 6-9, Hiranomach 2-chome, Chuo-ku, Osaka 541-0046, Japan.
LICENSE AGREEMENTLicense Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT (this “Agreement”) dated as of October 22, 2004 (the “Effective Date”), is entered into between MediciNova, Inc., a Delaware corporation (“MN”) having a place of business located at 4350 La Jolla Village Drive, Suite 950, San Diego, California 92122, U.S.A., and Kyorin Pharmaceutical Co., Ltd., a Japanese corporation (“KR”), having a place of business located at 5, Kanda Surugadai 2-chome, Chiyoda-ku, Tokyo 101-8311, Japan.
Master Services AgreementMaster Services Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • California
** CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
LICENSE AGREEMENTLicense Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT (“Agreement”) dated as of March 14, 2002 (“Effective Date”), is entered into between MediciNova, Inc., a Delaware corporation (“MN”) having a place of business located at 4540 Towne Centre Court, San Diego, California 92121, U.S.A., and Kyorin Pharmaceutical Co., Ltd., a Japanese corporation (“KR”), having a place of business located at 5, Kanda Surugadai 2-chome, Chiyoda-ku, Tokyo 101-8311, Japan.
CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.License Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT effective as of June 19, 2002 (“Effective Date”), by and between Angiogene Pharmaceuticals, Ltd., a company organized and existing under the laws of Scotland having its registered office at 37 Queen Street, Edinburgh, Scotland, and a principal office at Magdalen Centre, The Oxford Science Park, Oxford OX4 4GA United Kingdom (“ANGIOGENE”) and MediciNova, Inc., a corporation organized and existing under the laws of the State of Delaware, United States, and having its principal office at 4540 Towne Centre Court, San Diego, CA 92121 United States (“MEDICINOVA”).
CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.License Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT effective as of June 1, 2003 (“Effective Date”), by and between RIKEN, a company organized and existing under the laws of Japan having its registered office at 2-1 Hirokawa, Wako-shi, Saitama 351-0198, Japan (“RIKEN”), Dr. Katsuhiko Mikoshiba, an individual having an address at 2-19-25 Inokashira, Mitaka, Tokyo, Japan (“MIKOSHIBA”) and MediciNova, Inc., a corporation organized and existing under the laws of the State of Delaware, United States, and having its principal office at 4370 La Jolla Village Drive, Suite 400, San Diego, CA 92122 United States (“MEDICINOVA”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • New York
This Exclusive License Agreement (the “Agreement”) is made as of this 25th day of February, 2004 (the “Effective Date”) by and between Kissei Pharmaceutical Co., Ltd., a corporation duly organized and existing under the laws of Japan and having its registered office at 19-48, Yoshino, Matsumoto-City, Nagano-Prefecture 399-8710, Japan (“Kissei”) and MediciNova, Inc., a corporation duly organized and existing under the laws of the State of Delaware, United States and having its registered office at 4350 La Jolla Village Dr., Ste. 950, San Diego, California 92122, USA (“MediciNova”). Each of Kissei and MediciNova is referred to herein as a “Party” and collectively, as the “Parties.”
CONSULTING AGREEMENTConsulting Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • California
This AGREEMENT dated as of November 22, 2004 (the “Effective Date”), is by and between MediciNova, Inc., a Delaware corporation having an office at 4350 La Jolla Village Drive, Suite 950, San Diego CA 92122 (the “Company”) and Yuichi Iwaki, M.D., Ph.D. (the “Consultant”).
Master Services AgreementMaster Services Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • California
** CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
